Compare ETON & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | KALV |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 551.2M |
| IPO Year | 2018 | N/A |
| Metric | ETON | KALV |
|---|---|---|
| Price | $16.71 | $16.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $29.67 | $26.43 |
| AVG Volume (30 Days) | 277.8K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,316,000.00 | $1,426,000.00 |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $7.30 |
| 52 Week High | $23.00 | $17.28 |
| Indicator | ETON | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 70.46 |
| Support Level | $16.13 | $15.88 |
| Resistance Level | $17.05 | $17.10 |
| Average True Range (ATR) | 0.76 | 1.08 |
| MACD | 0.16 | 0.22 |
| Stochastic Oscillator | 79.06 | 96.52 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.